Global investment banks expect gold to extend its record-breaking price rally into 2025 and China's stock market to edge up the next year, according to their latest forecasts on major asset classes including stocks, bonds, commodities.
Goldman Sachs expects the central banks of emerging and developed economies to continue their accommodative monetary policies into 2025.
The investment bank anticipates an average interest rate reduction of 116 basis points in developed economies and 114 basis points in emerging markets over the next year.
In terms of commodities, Goldman Sachs is optimistic about gold prices, forecasting that they could reach 3,000 U.S. dollars per ounce by 2025 mainly due to increased central bank purchases and anticipated rate cuts by the U.S. Federal Reserve.
J.P. Morgan Chase shares a positive outlook on gold prices, but sets a lower target of 2,850 U.S. dollars per ounce.
Goldman Sachs is also bullish on Chinese equities, maintaining an "overweight" position on stocks listed in the Chinese mainland and the Hong Kong Special Administrative Region.
It expects the MSCI China Index to rise by 15 percent and the China Securities Index 300 by 13 percent in 2025.
J.P. Morgan Asset Management forecasts an average annual return of 7.8 percent for Chinese equities over the next 10 to 15 years, driven by China's focus on enhancing productive forces.
Int'l investment banks bullish on gold, Chinese equities in 2025
A Chinese foreign ministry spokesperson said on Tuesday that the United States should cherish the goodwill of China and safeguard the hard-won positive situation of China-U.S. cooperation on drug control.
The spokesperson made the remarks after U.S. President-elect Donald Trump threatened to slap an additional 10 percent tariff on all Chinese imports.
The spokesperson said that China has the strictest drug control policy in the world and enforces it in the fullest way.
Noting that Fentanyl is a problem for the U.S., the spokesperson said in the spirit of humanitarianism, China has provided support to the U.S. in dealing with fentanyl-related issues. In 2019, China scheduled all fentanyl-related substances as early as in 2019 - the first country ever to do so.
China and the U.S. have carried out extensive and in-depth drug control cooperation and achieved remarkable results, which is obvious to all, said the spokesperson.
The spokesperson said China is willing to continue to carry out drug control cooperation with the U.S. on the basis of equality, mutual benefit and mutual respect, urging the U.S. side to cherish China's goodwill and maintain the hard-won positive momentum of the China-U.S. anti-drug cooperation.
China urges US to safeguard drug-control cooperation
China urges US to safeguard drug-control cooperation